The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …

Background Systemic therapies have improved the management of hepatocellular
carcinoma, but there is still a need to further enhance overall survival in first-line advanced …

Objective Lenvatinib and sorafenib are first-line oral multikinase inhibitors approved for the
treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the primary …

Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular
carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy …

Purpose: Immune checkpoint inhibitors combined with antiangiogenic agents produce
benefits in the treatment of advanced hepatocellular carcinoma (HCC). We investigated the …

Abstract Background & Aims Single-agent anti-PD1 checkpoint inhibitors convey
outstanding clinical benefits in a small fraction (∼ 20%) of patients with advanced …

Purpose To compare the efficacy and safety of the combination of transcatheter arterial
chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) …

Purpose To evaluate the efficacy and safety of lenvatinib combined with programmed death
receptor-1 signaling inhibitors plus transarterial chemoembolization (LePD1-TACE) for …

Abstract Background & Aims Immune checkpoint inhibitors (ICIs) alone or in combination
with other ICIs or vascular endothelial growth factor pathway inhibitors are therapeutic …

Background Transarterial chemoembolisation (TACE) is standard care for unresectable, non-
metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and …